Waylivra (volanesorsen)

$14,122.19

Waylivra (volanesorsen) is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and plasma triglycerides lowering therapy has been inadequate.

DISEASE INDICATIONS

Familial chylomicronemia syndrome (FCS)

MANUFACTURER

Akcea Therapeutics Ireland Limited

USAGE

Subcutaneous

MEDICINE APPROVED BY

  • European Medical Agency (EMA)

    PATIENTS HELPED

    • Over 1.2 million patients reached

    • More than 11,000 patients helped

    • 100% successful deliveries to 88 countries

This content has been reviewed by a Medical Doctor.
WAYLIVRA (VOLANESORSEN) Package

285 mg in 1.5 mL

Reviews

There are no reviews yet.

Be the first to review “Waylivra (volanesorsen)”

Your email address will not be published. Required fields are marked *

Shopping Cart